KOL Connect

Ernexa Therapeutics Pharma
June 09, 2026

Ira S. Winer, MD, PhD, FACOG, Scientific Advisory Board Member at Ernexa Therapeutics, Professor in the Division of Gynecologic Oncology at Wayne State University School of Medicine and gynecologic oncologist at the Barbara Ann Karmanos Cancer Institute, provides perspective on the significant unmet need that continues to exist in ovarian cancer, limitations associated with current treatment approaches and the growing focus on overcoming immunologically “cold” tumors that remain resistant to many immune-based therapies.

What This Means

Featuring Autonomix
June 04, 2026

Dr. Toufic Kachaamy, Key Opinion Leader and Chief of Medicine at City of Hope in Phoenix, AZ, discusses the clinical significance of data presented by Autonomix Medical at the Society of Surgical Oncology Annual Meeting (SSO), highlighting the importance of the work being selected for a podium presentation and its relevance to the surgical oncology community.

What This Means

Featuring Moleculin
June 04, 2026

Walter Klemp, Chairman and Chief Executive Offier of Moleculin, discusses the Company’s recent news announcing that the 45th subject has been enrolled in its pivotal Phase 2B/3 MIRACLE trial evaluating Annamycin in combination with cytarabine (AnnAraC) for the treatment of adult subjects with relapsed or refractory acute myeloid leukemia (R/R AML).

CEO Connect

Featuring CNS Pharmaceuticals
May 20, 2026

Rami Levin, President and Chief Executive Officer of CNS Pharmaceuticals, highlighted the Company’s recent $22.5 million financing, including its strategic pivot, progress made to date and how the capital positions CNS to identify and advance new assets aimed at driving long-term shareholder value.

KOL Connect

Featuring AIM Immuno
May 14, 2026

Professor Doctor Casper H.J. van Eijck, MD, PhD, Professor and Pancreato-biliary Surgeon at Erasmus Medical Center (“Erasmus MC”) and a consultant for AIM, and AIM Chief Executive Officer Thomas K. Equels, MS, JD, participate in a Virtual Investor KOL Connect segment.

Prof. Dr. van Eijck, a globally recognized pancreatic cancer clinical expert and the foremost expert in the use of Ampligen in pancreatic cancer, examines Ampligen’s mechanism of action, its potential to provide a positive immunotherapeutic approach, existing clinical data, development strategy, and anticipated regulatory milestones, supporting AIM’s focused commitment to advancing a potential new treatment option for patients with late-stage pancreatic cancer.

KOL Connect

Featuring Ernexa Therapeutics
May 11, 2026

Dr. Robert Pierce, Chief Scientific Office for Ernexa, provides insight into the complexities of ovarian cancer, highlights the patient journey from diagnosis through treatment, and emphasizes the persistent unmet need for more effective and durable treatment options.

Dr. Pierce also outlines the evolving treatment landscape and shares his perspective on how Ernexa is approaching ovarian cancer differently at the biological level. He discusses the Company’s lead product candidate, ERNA101, and its potential to improve outcomes and enhance the patient experience compared to existing therapies.

What This Means

Featuring Daré Bioscience
March 12, 2026

Sabrina Martucci Johnson, President and CEO of Daré Bioscience, discusses the significance of the FDA’s IND clearance and how this milestone allows Daré to advance DARE-HPV into Phase 2 clinical development in alignment with Daré’s broader strategy to address unmet needs in women’s health.